The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss FiercePharma
Bristol-Myers Squibb executives said merging with Celgene delivers six near-term launches—with $15 billion in peak sales potential—into their hands.
The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss FiercePharma
Bristol-Myers Squibb executives said merging with Celgene delivers six near-term launches—with $15 billion in peak sales potential—into their hands.